Form D · Pharmaceuticals
Delpor, Inc.
San Francisco, CA · CIK 0001494224
Offering snapshot reported Oct 3, 2013 · SEC filing
- Reported sold
- $470K Offering amount: $500K
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 9, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 3, 2013 | Initial | $470,000 | No comparison | 8 | SEC filing |
| Jun 16, 2010 | Initial | $900,492 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-203964
The Total Offering Amount and Total Amount Sold include cancellation of debt.
Source: Form D, filed Oct 3, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nicolaos Arvanitidis | Director |
| Douglas Crawford | Director |
| Ernest Mario | Director |
| Francis Martin | Director, Executive |
| Anastassios Nicolaou | Director, Executive |
| Anastassios Nicolau | Director, Executive |
| Carl Spetzler | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
409 Illinois St.
San Francisco, CA, 94158
San Francisco, CA, 94158